PMID- 23452053
OWN - NLM
STAT- MEDLINE
DCOM- 20130826
LR  - 20131121
IS  - 1744-7658 (Electronic)
IS  - 1354-3784 (Linking)
VI  - 22
IP  - 4
DP  - 2013 Apr
TI  - Differentiating sodium-glucose co-transporter-2 inhibitors in development for the 
      treatment of type 2 diabetes mellitus.
PG  - 463-86
LID - 10.1517/13543784.2013.774372 [doi]
AB  - INTRODUCTION: Sodium-glucose co-transporter-2 (SGLT2) inhibitors are a novel 
      class of agents for the treatment of type 2 diabetes mellitus (T2DM). By 
      inhibiting SGLT2, they prevent renal glucose reabsorption, resulting in 
      glucosuria. AREAS COVERED: The rationale for development of SGLT2 inhibitors is 
      reviewed, with particular focus on the nine SGLT2 inhibitors currently in 
      development. The authors compare the potency and SGLT2 selectivity of the agents, 
      as well as the results from both animal and clinical studies, considering the 
      potential implications they may have for clinical use. EXPERT OPINION: Current 
      evidence suggests that SGLT2 inhibitors have similar efficacy in terms of 
      glycemic control and also demonstrate benefits beyond glycemic reductions, 
      including reductions in body weight and modest reductions in blood pressure. 
      Additionally, they appear to preserve beta-cell function and improve insulin 
      sensitivity. Their mechanism of action allows for combination of SGLT2 inhibitors 
      with other antidiabetic drugs and use across the treatment continuum for T2DM. 
      Potential differences in safety and efficacy based on observed differences in 
      potency and selectivity among the SGLT2 inhibitors, particularly versus SGLT1, 
      remain to be seen. Further long-term data, including post-marketing surveillance, 
      are required to fully determine the safety profile of SGLT2 inhibitors in large 
      patient groups.
FAU - Washburn, William N
AU  - Washburn WN
AD  - Metabolic Diseases Chemistry, Research and Development, Bristol-Myers-Squibb Co. 
      Princeton, NJ, USA. William.Washburn@bms.com
FAU - Poucher, Simon M
AU  - Poucher SM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20130301
PL  - England
TA  - Expert Opin Investig Drugs
JT  - Expert opinion on investigational drugs
JID - 9434197
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transport Proteins)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Type 2/*drug therapy/metabolism
MH  - Disease Models, Animal
MH  - Glucose/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Kidney/metabolism
MH  - Sodium-Glucose Transport Proteins/*antagonists & inhibitors/metabolism
EDAT- 2013/03/05 06:00
MHDA- 2013/08/27 06:00
CRDT- 2013/03/05 06:00
PHST- 2013/03/05 06:00 [entrez]
PHST- 2013/03/05 06:00 [pubmed]
PHST- 2013/08/27 06:00 [medline]
AID - 10.1517/13543784.2013.774372 [doi]
PST - ppublish
SO  - Expert Opin Investig Drugs. 2013 Apr;22(4):463-86. doi: 
      10.1517/13543784.2013.774372. Epub 2013 Mar 1.